Congestive Heart Failure (Nursing)

Daniel Brito; Ahmad Malik; Sarosh Vaqar; Lovely Chhabra; Pirbhat Shams

Congestive Heart Failure (Nursing)

Learning Outcome

Understand the clinical signs and symptoms of heart failure
Understand the pathophysiology of heart failure
Review the lifestyle modifications recommended for patients with heart failure

Introduction

Heart failure is a common and complex clinical syndrome that results from any functional or structural heart disorder, impairing ventricular filling or ejection of blood to the systemic circulation to meet the body's needs. Heart failure can be caused by several different diseases. Most patients with heart failure have symptoms due to impaired left ventricular myocardial function. Patients usually present with dyspnea, fatigue, decreased exercise tolerance, and fluid retention, seen as pulmonary and peripheral edema.[1]

Heart failure due to left ventricular dysfunction is categorized according to left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (LVEF 40% or less), known as HFrEF, and heart failure with preserved ejection fraction (LVEF greater than 40%); known as HFpEF.[2]

Nursing Diagnosis

Decreased cardiac output
Activity intolerance
Excess fluid volume
Risk for impaired skin integrity
Ineffective tissue perfusion
Ineffective breathing pattern
Impaired gas exchange
Fatigue
Anxiety

Causes

Heart failure is caused by several disorders, including diseases affecting the pericardium, myocardium, endocardium, cardiac valves, vasculature, or metabolism. The most common causes of systolic dysfunction (HFrEF) are idiopathic dilated cardiomyopathy (DCM), coronary heart disease (ischemic), hypertension, and valvular disease. For diastolic dysfunction (HFpEF), similar conditions have been described as common causes, adding hypertrophic obstructive cardiomyopathy and restrictive cardiomyopathy.[1]

Risk Factors

Coronary artery disease
Myocardial infarction
Hypertension
Diabetes
Obesity
Smoking
Alcohol use disorder
Atrial fibrillation
Thyroid diseases
Congenital heart disease
Aortic stenosis

Assessment

Symptoms of heart failure include those due to excess fluid accumulation (dyspnea, orthopnea, edema, pain from hepatic congestion, and abdominal distention from ascites) and those due to a reduction in cardiac output (fatigue, weakness) most pronounced with physical exertion.[1]

Acute and subacute presentations (days to weeks) are characterized by shortness of breath at rest and/or with exertion, orthopnea, paroxysmal nocturnal dyspnea, and right upper quadrant discomfort due to acute hepatic congestion (right heart failure). Palpitations, with or without lightheadedness, can occur if patients develop atrial or ventricular tachyarrhythmias.

Chronic presentations (months) differ in that fatigue, anorexia, abdominal distension, and peripheral edema may be more pronounced than dyspnea. The anorexia is secondary to several factors, including poor perfusion of the splanchnic circulation, bowel edema, and nausea induced by hepatic congestion.[1]

Characteristic features:

Pulsus alternans phenomenon characterized by evenly spaced alternating strong and weak peripheral pulses.
Apical impulse: Laterally displaced past the midclavicular line, usually indicative of left ventricular enlargement.
S3 gallop: A low-frequency, brief vibration occurring in early diastole at the end of the rapid diastolic filling period of the right or left ventricle. It is the most sensitive indicator of ventricular dysfunction.
Peripheral edema
Pulmonary rales

New York Heart Association Functional Classification[3]

Based on symptoms, the patients can be classified using the New York Heart Association (NYHA) functional classification as follows:

Class I: Symptom onset with more than ordinary level of activity
Class II: Symptom onset with an ordinary level of activity
Class III: Symptom onset with minimal activity
Class IV: Symptoms at rest

Evaluation

Tests used in the evaluation of patients with HF include:

Electrocardiogram (ECG): Important for identifying evidence of acute or prior myocardial infarction or acute ischemia, rhythm abnormalities, such as atrial fibrillation.
Chest x-ray: Characteristic findings are cardiac-to-thoracic width ratio above 50%, cephalization of the pulmonary vessels, Kerley B-lines, and pleural effusions.
Blood test: Cardiac troponin (T or I), complete blood count, serum electrolytes, blood urea nitrogen, creatinine, liver function test, and brain natriuretic peptide (BNP). BNP (or NT-proBNP) level adds greater diagnostic value to the history and physical examination than other initial tests mentioned above.
Transthoracic echocardiogram: To determine ventricular function and hemodynamics.

Medical Management

Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitor, hydralazine plus nitrate, digoxin, and aldosterone antagonists can produce an improvement in symptoms and are indicated for patients with HF based on their functional classification and severity of symptoms. Combination therapy with these agents improves outcomes and reduces hospitalizations in patients with HF.[3]

Improved patient survival has been documented with the use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor neprilysin inhibitor, hydralazine plus nitrate, and aldosterone antagonists. More limited evidence of survival benefit is available for diuretic therapy. Diuretic therapy is mainly used for symptom control. Angiotensin receptor neprilysin inhibitors should not be given within 36 hrs of angiotensin-converting enzyme inhibitors dose.[3]

In African-Americans, hydralazine plus oral nitrate is indicated in patients with persistent NYHA class III to IV HF and LVEF less than 40%, despite optimal medical therapy (beta-blocker, angiotensin-converting enzyme inhibitors, ARB, aldosterone antagonist (if indicated), and diuretics.[3]

Device therapy: Implantable cardioverter-defibrillator (ICD) is used for primary or secondary prevention of sudden cardiac death. Cardiac resynchronization therapy with biventricular pacing can improve symptoms and survival in selected patients who are in sinus rhythm and have a reduced left ventricular ejection fraction and a prolonged QRS duration. Most patients who satisfy the criteria for cardiac resynchronization therapy implantation are also candidates for an implantable cardioverter-defibrillator and receive a combined device.[3]

A ventricular assist device (bridge to transplant or as a destination therapy) or cardiac transplant is reserved for those with severe disease despite all other measures.

Nursing Management

The nursing care plan for patients with HF should include:[4]

Relieving fluid overload symptoms
Relieving symptoms of anxiety and fatigue
Promoting physical activity
Increasing medication compliance
Decreasing adverse effects of treatment
Teaching patients about dietary restrictions
Teaching patient about self-monitoring of symptoms
Teaching patients about daily weight monitoring

When To Seek Help

Prompt assessment by the medical team is indicated in the following situations:

Worsening symptoms of fluid overload
Worsening hypoxia
Uncontrolled tachycardia regardless of the rhythm
Change in cardiac rhythm
Change in mental status
Decreased urinary output despite diuretic therapy

Monitoring

Patients with HF require frequent monitoring of vital signs, including oxygen saturation. They may also require constant monitoring of the heart rate and rhythm via telemetry monitoring. Frequent assessment and monitoring for symptoms is also indicated. All patients with HF require daily weight monitoring.

Coordination of Care

Heart failure is a serious disorder best managed by an interprofessional team that includes the primary care physician, emergency department physician, cardiologist, radiologist, cardiac nurses, internist, and cardiac surgeons. It is imperative to treat the cause of heart failure. Healthcare workers who look after these patients must be familiar with current guidelines on treatment. The risk factors for heart disease must be modified, and the clinical nurse should educate the patient on the importance of medication compliance and lifestyle modifications. When the condition is not managed appropriately, it is associated with high morbidity and mortality, including poor quality of life.[5]

Health Teaching and Health Promotion

Nursing care plans for patients with HF must include patient education to improve clinical outcomes and reduce hospital readmissions. Patients need education and guidance on self-monitoring of symptoms at home, medication compliance, daily weight monitoring, dietary sodium restriction to 2 to 3 g/day, and daily fluid restriction to 2 L/day. In addition, patients with HF need aggressive treatment for underlying risk factors and the potential triggers for HF exacerbations. Modifiable risk factors include diabetes mellitus, hypertension, obesity, nicotine use, alcohol use disorder, and recreational drug use, especially cocaine. Patients with sleep apnea and HF should be encouraged to use continuous positive airway pressure (CPAP) therapy as uncontrolled sleep apnea can also increase HF-associated morbidity and mortality.

Discharge Planning

Discharge planning for patients with HF must include patient education on medication management, medication compliance, low-sodium diet, fluid restriction, activity and exercise recommendations, smoking cessation, and learning to recognize the signs and symptoms of worsening HF. Discharge planning for patients with HF must also include follow-up appointments to ensure patients have a close medical follow-up after discharge. Nurse-driven education at the time of discharge has been shown to improve compliance with therapy and improve patient outcomes in heart failure.[6]

(Click Image to Enlarge)

congestive heart failure
Image courtesy S Bhimji MD

Details

References

[1]

Savarese G,Lund LH, Global Public Health Burden of Heart Failure. Cardiac failure review. 2017 Apr; [PubMed PMID: 28785469]

[2]

Nussbaumerová B,Rosolová H, Diagnosis of heart failure: the new classification of heart failure. Vnitrni lekarstvi. Fall 2018 [PubMed PMID: 30441997]

[3]

Ziaeian B,Fonarow GC, Epidemiology and aetiology of heart failure. Nature reviews. Cardiology. 2016 Jun; [PubMed PMID: 26935038]

[4]

Lind L,Ingelsson M,Sundstrom J,Ärnlöv J, Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open heart. 2021 Sep [PubMed PMID: 34518286]

[5]

Reddy YNV,Melenovsky V,Redfield MM,Nishimura RA,Borlaug BA, High-Output Heart Failure: A 15-Year Experience. Journal of the American College of Cardiology. 2016 Aug 2; [PubMed PMID: 27470455]

[6]

Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 3:141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29 [PubMed PMID: 31992061]

[7]

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7:135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25 [PubMed PMID: 28122885]

[8]

Wong CM,Hawkins NM,Jhund PS,MacDonald MR,Solomon SD,Granger CB,Yusuf S,Pfeffer MA,Swedberg K,Petrie MC,McMurray JJ, Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). Journal of the American College of Cardiology. 2013 Nov 12 [PubMed PMID: 23850914]

[9]

Yusuf S,Joseph P,Rangarajan S,Islam S,Mente A,Hystad P,Brauer M,Kutty VR,Gupta R,Wielgosz A,AlHabib KF,Dans A,Lopez-Jaramillo P,Avezum A,Lanas F,Oguz A,Kruger IM,Diaz R,Yusoff K,Mony P,Chifamba J,Yeates K,Kelishadi R,Yusufali A,Khatib R,Rahman O,Zatonska K,Iqbal R,Wei L,Bo H,Rosengren A,Kaur M,Mohan V,Lear SA,Teo KK,Leong D,O'Donnell M,McKee M,Dagenais G, Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet (London, England). 2020 Mar 7 [PubMed PMID: 31492503]

[10]

Kemp CD,Conte JV, The pathophysiology of heart failure. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2012 Sep-Oct; [PubMed PMID: 22227365]

[11]

CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The New England journal of medicine. 1987 Jun 4:316(23):1429-35 [PubMed PMID: 2883575]

[12]

Obokata M,Reddy YNV,Borlaug BA, Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC. Cardiovascular imaging. 2020 Jan; [PubMed PMID: 31202759]

[13]

King M,Kingery J,Casey B, Diagnosis and evaluation of heart failure. American family physician. 2012 Jun 15 [PubMed PMID: 22962896]

[14]

Ali AS,Rybicki BA,Alam M,Wulbrecht N,Richer-Cornish K,Khaja F,Sabbah HN,Goldstein S, Clinical predictors of heart failure in patients with first acute myocardial infarction. American heart journal. 1999 Dec [PubMed PMID: 10577445]

[15]

Klein L,O'Connor CM,Leimberger JD,Gattis-Stough W,Piña IL,Felker GM,Adams KF Jr,Califf RM,Gheorghiade M,OPTIME-CHF Investigators., Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17 [PubMed PMID: 15867182]

[16]

Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE Jr,Drazner MH,Fonarow GC,Geraci SA,Horwich T,Januzzi JL,Johnson MR,Kasper EK,Levy WC,Masoudi FA,McBride PE,McMurray JJ,Mitchell JE,Peterson PN,Riegel B,Sam F,Stevenson LW,Tang WH,Tsai EJ,Wilkoff BL,American College of Cardiology Foundation.,American Heart Association Task Force on Practice Guidelines., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013 Oct 15; [PubMed PMID: 23747642]

[17]

Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE Jr,Colvin MM,Drazner MH,Filippatos GS,Fonarow GC,Givertz MM,Hollenberg SM,Lindenfeld J,Masoudi FA,McBride PE,Peterson PN,Stevenson LW,Westlake C, 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. 2017 Aug 8; [PubMed PMID: 28461007]

[18]

Jain S,Londono FJ,Segers P,Gillebert TC,De Buyzere M,Chirinos JA, MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Current heart failure reports. 2016 Feb [PubMed PMID: 26780916]

[19]

Hacker M,Hoyer X,Kupzyk S,La Fougere C,Kois J,Stempfle HU,Tiling R,Hahn K,Störk S, Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. The international journal of cardiovascular imaging. 2006 Jun-Aug; [PubMed PMID: 16328851]

[20]

Okuda K,Nakajima K,Kitamura C,Kirihara Y,Hashimoto M,Kinuya S, Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity. Scientific reports. 2020 Dec 14; [PubMed PMID: 33318541]

[21]

Ferdinand KC,Elkayam U,Mancini D,Ofili E,Piña I,Anand I,Feldman AM,McNamara D,Leggett C, Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. The American journal of cardiology. 2014 Jul 1 [PubMed PMID: 24846808]

[22]

Bhatt AS,Vaduganathan M,Claggett BL,Liu J,Packer M,Desai AS,Lefkowitz MP,Rouleau JL,Shi VC,Zile MR,Swedberg K,Vardeny O,McMurray JJV,Solomon SD, Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. European journal of heart failure. 2021 Sep [PubMed PMID: 34101308]

[23]

Beygui F,Cayla G,Roule V,Roubille F,Delarche N,Silvain J,Van Belle E,Belle L,Galinier M,Motreff P,Cornillet L,Collet JP,Furber A,Goldstein P,Ecollan P,Legallois D,Lebon A,Rousseau H,Machecourt J,Zannad F,Vicaut E,Montalescot G,ALBATROSS Investigators., Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. Journal of the American College of Cardiology. 2016 Apr 26 [PubMed PMID: 27102506]

[24]

Imamura T,Narang N, Comment on: Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: Rationale and design of SHIFT-AHF trial. ESC heart failure. 2021 Apr; [PubMed PMID: 33638613]

[25]

Ezekowitz JA,Zheng Y,Cohen-Solal A,Melenovský V,Escobedo J,Butler J,Hernandez AF,Lam CSP,O'Connor CM,Pieske B,Ponikowski P,Voors AA,deFilippi C,Westerhout CM,McMullan C,Roessig L,Armstrong PW,VICTORIA Study Group., Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation. 2021 Aug 25 [PubMed PMID: 34432985]

[26]

van der Meer P,Gaggin HK,Dec GW, ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. Journal of the American College of Cardiology. 2019 Jun 4 [PubMed PMID: 31146820]

[27]

Ilieșiu AM,Hodorogea AS, Treatment of Heart Failure with Preserved Ejection Fraction. Advances in experimental medicine and biology. 2018 [PubMed PMID: 29498023]

[28]

[29]

Lucas C,Johnson W,Hamilton MA,Fonarow GC,Woo MA,Flavell CM,Creaser JA,Stevenson LW, Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. American heart journal. 2000 Dec [PubMed PMID: 11099986]

[30]

Rider I,Sorensen M,Brady WJ,Gottlieb M,Benson S,Koyfman A,Long B, Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. The American journal of emergency medicine. 2021 Sep 2 [PubMed PMID: 34500232]

[31]

Habal MV,Garan AR, Long-term management of end-stage heart failure. Best practice & research. Clinical anaesthesiology. 2017 Jun [PubMed PMID: 29110789]

[32]

McMurray JJ,Pfeffer MA, Heart failure. Lancet (London, England). 2005 May 28-Jun 3 [PubMed PMID: 15924986]

[33]

Correale M,Mazzeo P,Mallardi A,Leopizzi A,Tricarico L,Fortunato M,Magnesa M,Tucci S,Maiellaro P,Pastore G,Lamacchia O,Iacoviello M,Di Biase M,Brunetti ND, Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. Cardiovascular drugs and therapy. 2021 Sep 14; [PubMed PMID: 34519913]

[34]

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. 2016 Jul 14:37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20 [PubMed PMID: 27206819]